October 1998

Trimethylpsoralen Bath PUVA Is a Remittive Treatment for Psoriasis VulgarisEvidence That Epidermal Immunocytes Are Direct Therapeutic Targets

Author Affiliations

From the Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY.


Copyright 1998 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.1998

Arch Dermatol. 1998;134(10):1263-1268. doi:10.1001/archderm.134.10.1263

Background  Psoriasis vulgaris can be effectively treated with trimethylpsoralen (TMP) bath PUVA therapy (psoralen plus UVA), but no data exist on the extent to which psoriatic pathology is affected by this treatment, or on its cellular mechanism of action.

Observations  Eleven patients with recalcitrant psoriasis vulgaris were treated with TMP bath PUVA therapy and observed through clinical and histological measures. Clinical resolution of psoriasis was achieved in 10 of 11 patients. Histopathological resolution of epidermal hyperplasia (marked by keratin 16 expression) was achieved in 90% of individuals treated with TMP bath PUVA. Epidermal acanthosis was reduced by 40% at 2 weeks and 66% by the end of treatment. Epidermal improvement correlated best with reduction in intraepidermal T lymphocytes, which were reduced by 76% at 2 weeks of treatment and 93% at the end of treatment. Furthermore, following TMP bath PUVA therapy, the numbers of epidermal CD1a+ Langerhans cells were markedly reduced, and CD86+ cells were eliminated. Through in vitro assays, TMP was found to be about 10000-fold more active as a lymphotoxic agent compared with 8-methoxypsoralen (8-MOP). Additionally, at physiologic concentrations, lymphocytes were killed more readily by TMP PUVA (TMP plus UVA) than were keratinocytes.

Conclusions  Treatment with TMP bath PUVA was effective in treating moderate to severe psoriasis, even in darker pigmented individuals. It is likely that this treatment ameliorates psoriasis through direct effects on activated leukocytes in lesional skin.

CONVENTIONAL PUVA therapy (oral administration of 8-methoxypsoralen [8-MOP] followed by UV-A irradiation) has been used successfully for more than 20 years to treat difficult cases of psoriasis.13 While short-term adverse effects such as nausea and malaise limit treatment in some patients, there is increasing concern over PUVA-induced cutaneous carcinomas and melanomas that will effectively limit its long-term use in most patients.49 Bath PUVA therapy has been suggested as a potentially safer alternative to conventional PUVA.1014 Bath PUVA therapy (using trimethylpsoralen [TMP]) has been used for more than 20 years in Sweden and Finland without an observed increase in the number of skin cancers.1014 Trimethylpsoralen, which is more hydrophobic than 8-MOP, could potentially differ in its mechanism of action in psoriasis, especially via topical application. Unfortunately, no data exist that delineate the pathological or cellular effects of TMP vs 8-MOP in psoriatic skin lesions during treatment. In this study, we examined the clinical, epidermal, and immunologic effects of TMP bath PUVA therapy on lesional skin. Trimethylpsoralen was found to clear psoriatic plaques while reversing pathological hyperplasia and epidermal infiltration by CD3+ and CD86+ immunocytes.


Thirteen patients (11 men and 2 women) with long-standing psoriasis vulgaris (mean disease duration, 16 years) were sequentially enrolled into our TMP bath PUVA study. These patients had 10% to 90% (mean, 44%) skin surface involvement and had been treated previously with a variety of agents. Six patients had Fitzpatrick skin types V or VI. Eleven of 13 patients completed the study, while 2 patients were noncompliant with treatment and were dropped from the study. Data from 1 of the 11 patients who completed the study (who achieved clinical clearing) were not included in histological analyses because the final biopsy was refused.


Minimum phototoxic dose (MPD) testing to UVA was performed by soaking an extremity (usually an arm) in a TMP solution of 0.167 mg/L for 15 minutes and then exposing 2×2-cm patches to UVA in amounts ranging from 0.2 to 2.0 J/cm2. Photopatches were read at 12, 24, 48, and 72 hours following UVA exposure. The starting UVA dose was 50% to 75% of the MPD. In patients for whom the MPD was indeterminate, conservative initial exposures of 0.2 to 0.4 J/cm2 were given. Treatment was delivered on an alternate-day schedule. Subsequent doses were increased by 0.1 to 0.5 J/cm2, depending on skin type and lack of phototoxic effects from prior treatment. The goal for each treatment was to attain slight (+/-) erythema following UVA exposure. The patients were supplied with an emollient (Aquabase) to apply to their skin as desired.

The TMP was purchased as 5-mg tablets for oral administration (ICN Pharmaceuticals, Costa Mesa, Calif). An ethanol solution was prepared by crushing tablets and extracting the powder, then combining it with 20 mL of absolute ethanol at 60°C for 12 to 24 hours, after which the solution was filtered to remove suspended filler. A measured amount of TMP solution (25 mg in 100 mL of ethanol) was added to 150 L of lukewarm water in a bathtub (final concentration, 0.167 mg/L). The patient then sat submerged up to the neck for 15 minutes. Following the bath, the patient dried off with a towel and immediately entered the light box while wearing UV-protecting glasses and a groin shield. The phototherapy unit (model 57000, Psoralite Corporation, Columbia, SC) delivered approximately 13 mJ/cm2 of UVA (measured with a UVA meter from National Biological Corporation, Twinsburg, Ohio).


Biopsies of lesional skin were performed before treatment, after 2 weeks of treatment, and at the end of treatment. Skin biopsy specimens were frozen in optimum cutting temperature compound solution for histological analysis. Cryostat sections were stained with CD3 (Becton Dickinson, San Jose, Calif), Ks8.12 (Sigma Aldrich Inc, St Louis, Mo), CD1a (Becton Dickinson), or CD86 (FUN-1 clone, Pharmingen, San Diego, Calif) monoclonal antibodies as previously described.15 Epidermal thickness was measured on digitized micrographs using the National Institutes of Health Image software.16


Table 1 summarizes the clinical responses to TMP bath PUVA therapy in our patient population. These patients had skin types ranging from Fitzpatrick types II to VI, but more than 50% of patients who completed treatment had skin types V or VI. All patients had significant improvement in clinical severity measures. Two weeks after starting treatment, a 25% mean improvement in plaque severity was measured (P<.001). At the end of treatment, an 83% mean reduction in disease severity was measured (P<.001). All patients showed clinical benefit, with 10 of 11 patients having clear skin or only trace disease at the conclusion of treatment. The 1 patient who failed to undergo a final skin biopsy (who achieved clinical clearing) was not included in the histological data set.

Image not available
Reduction in Disease-Related Parameters During Treatment*

Biopsy specimens obtained from lesional skin before treatment, after 2 weeks, and at the end of treatment were examined for disease-related pathology using histochemistry and computer-assisted image analysis. As shown in Table 1, mean epidermal thickness was reduced by 40% after 2 weeks (P<.001) and 66% by the end of treatment (P<.001). To determine whether pathological keratin expression was reversed by this treatment, biopsy specimens were examined for the expression of keratin 16 (Figure 1). Keratin 16 was expressed in suprabasal keratinocytes in all pretreatment biopsy specimens and continued to be expressed in 9 of 10 patients after 2 weeks of PUVA treatment. At the conclusion of treatment, keratin 16 was expressed in only 1 of the 10 psoriatic lesions. Because keratin 16 is expressed only in hyperplastic epidermis undergoing "regenerative" maturation,17 these staining results indicate reversal of regenerative growth by TMP bath PUVA treatment.

Figure 1.
Image not available

Keratin 16 expression in psoriatic lesional epidermis before (A), at 2 weeks (B), and after trimethylpsoralen (TMP) therapy (C). The effects of TMP bath plus UVA therapy on epidermal and dermal T-lymphocyte infiltration as visualized by CD3+ antibody staining on skin biopsy specimens obtained from another patient before (D), at 2 weeks (E), and after treatment (F).

Previous studies have suggested that T lymphocytes may be the major cellular target of PUVA (8-MOP plus UVA) therapy.18,19 Accordingly, we sought to determine the lymphocyte-depleting effects of TMP PUVA therapy in psoriatic tissue and to measure direct lymphotoxic effects of TMP in vitro. The effects of TMP bath PUVA therapy on CD3+ lymphocytes in psoriatic lesions are presented in Table 1. Two weeks after starting PUVA treatment, there was a striking reduction in intraepidermal T lymphocytes (mean decrease, 76%; P <.001), but only a modest reduction (mean decrease, 22%) in T lymphocytes located in the papillary dermis. By the end of treatment, intraepidermal T lymphocytes had been reduced by 93% and dermal lymphocytes had been reduced by 62%. After 2 weeks of treatment, reductions in epidermal acanthosis were highly correlated with reductions in intraepidermal CD3+ cells (r=0.87), and less correlated with dermal T-lymphocyte reductions (r=0.58). For all study points (Figure 1) epidermal thickness was more highly correlated with the number of epidermal T lymphocytes compared with dermal cells. These data are consistent with epidermal changes being induced primarily by the intraepidermal T-lymphocyte subset.

The ability of PUVA to decrease inflammation in psoriatic lesions could also be mediated through its depleting actions on Langerhans cells.2024 In the unaffected skin of patients with psoriasis, CD1a+ Langerhans cells are present throughout the epidermis, but few cells express detectable levels of the costimulatory molecule B7-2 (CD86), as shown in Figure 2 . In contrast, CD1a+ cells are mostly located in more differentiated regions of lesional epidermis and numerous CD86+ cells are also present in these areas. Following TMP bath PUVA therapy, there was a marked reduction in the number of CD1a+ cells in the epidermis, and CD86+ cells were eliminated. Hence, Langerhans cells (particularly activated CD86+ cells) appear to be depleted from psoriatic lesions by TMP bath PUVA treatment.

Figure 2.
Image not available

The effects of trimethylpsoralen (TMP) bath plus UVA therapy on expression of CD1a and CD86 in dendritic cells in normal skin (A and B), lesional plaques (C and D), and treated lesional skin (E and F). Arrows indicate dendritic CD86+ Langerhans cell, with close-up in lower right corner (D). Black bars indicate 100 µm.


Finally, we sought to determine the relative cytotoxic effects of TMP and 8-MOP on activated lymphocytes. Previous studies indicated that 8-MOP plus UVA can selectively induce T lymphocytes to undergo apoptotic cell death.18,19 We used several different assays to evaluate the effects of TMP on mitogen-activated peripheral blood T lymphocytes. Since apoptotic cells eventually disintegrate into subcellular apoptotic fragments, PUVA-induced cytotoxic effects can be quantified by measuring reductions in a particular target cell population. Hence, the cytotoxicity of 8-MOP or TMP for T lymphocytes was assessed by enumerating CD3+ cells through flow cytometry. T lymphocyte numbers were reduced 89% by treatment with 0.01 ng/mL of TMP PUVA, 98% by treatment with 0.1 ng/mL of TMP PUVA, and 92% by treatment with 100 ng/mL of 8-MOP plus UVA. Cultures showed T-lymphocyte size and granularity shifts that typify apoptosis19 and subgenomic DNA fragmentation using flow cytometry.18 Based on relative concentrations of psoralens required to produce cytotoxicity, mitogen-activated T lymphocytes appeared to be about 10000-fold more sensitive to TMP than to 8-MOP.

Finally, the relative sensitivity of epidermal keratinocytes vs lymphocytes to TMP PUVA therapy was measured using flow cytometry–based viability and cell counting assays. As was the case for 8-MOP PUVA therapy,18 lymphocytes were killed by TMP PUVA therapy, but keratinocytes were relatively resistant (data not shown).


Currently, psoriasis is considered to be an immune-mediated disease in which activated T lymphocytes trigger rapid keratinocyte proliferation, altered epidermal differentiation, and neovascularization.25 In turn, the activation of T lymphocytes is regulated by dendritic cells in psoriatic lesions that have up-regulated B7 costimulatory molecules and can serve as potent stimulators of resting T lymphocytes.26 The clinical importance of an immune pathoetiology is that it may be possible to develop immune-directed therapy that minimizes toxicity to other cells. In fact, 8-MOP is a potent cytotoxic agent for T lymphocytes following activation by UVA, but it is not entirely selective in its actions.18,19 Previous studies have shown that 8-MOP, when used in PUVA bath treatment, produces profound depletion of lesion-infiltrating T lymphocytes and that pathological epidermal hyperplasia is reversed following a course of treatment.15 Although both TMP and 8-MOP PUVA therapy reverse pathologic keratinocyte hyperplasia (defined by keratin 16 expression), one important difference is that epidermal Langerhans cells were strongly depleted by TMP PUVA therapy in lesional psoriatic epidermis, whereas 8-MOP did not produce marked reductions in lesional Langerhans cells.15 The ability of TMP PUVA therapy to reduce expression of CD86 in epidermal cells (presumably Langerhans cells) provides yet another mechanism for immune suppression, ie, T-cell costimulation should be diminished due to less B7 expression on dendritic cells.

Clinical observations suggest that TMP bath PUVA therapy might be less carcinogenic than conventional PUVA.1014 In animal and bacterial model systems, TMP and 8-MOP have been found to be potent carcinogens.2733 It is possible that TMP will be proven to be highly carcinogenic in psoriatic patients once sufficient exposure is given, and this possibility cannot be excluded with certainty by present data.1014 However, if this type of treatment does eventually prove to be less carcinogenic, one potential explanation could be that topical psoralens cause different cellular effects than systemic psoralens. Based on previous studies,16,34 it is likely that intraepidermal T lymphocytes (as well as Langerhans cells that support ongoing T-lymphocyte activation) are the main cellular targets for therapeutic improvement. Epidermal psoralen levels have been measured at higher than 250 pg/g from bathing in TMP solutions equivalent to those used in this study.35 Since TMP concentrations of only 10 pg/mL were highly cytotoxic for activated T lymphocytes in our in vitro studies, actual psoralen levels attained in the epidermis from in vivo treatment should be sufficient to target T lymphocytes (even if UVA levels that penetrate epidermis are <2 J/cm2). The marked depletion of intraepidermal T lymphocytes following TMP bath PUVA therapy is consistent with the direct cytotoxic effects on this cell type, but the reduced T-lymphocyte infiltration could also be mediated by elimination of CD86+ dendritic cells from skin lesions. Conceivably, topically applied TMP might have limited penetration in the epidermis such that cross-linking of DNA occurs mostly in differentiated cell layers (where CD3+ and CD86+ cells predominate). It is theoretically possible that therapeutic effects could be separable from carcinogenic effects based on differential psoralen distribution and differences in the location of target cells.

In the end, we found TMP bath PUVA therapy to be well tolerated and highly effective at producing clinical and histological resolution of psoriasis. The ability of TMP bath PUVA therapy to eliminate activated Langerhans cells and T lymphocytes within the epidermis is likely to underlie its potent therapeutic actions in psoriasis. Although safety data on the carcinogenic risk of TMP bath treatment are less complete than for oral 8-MOP, we believe that TMP bath PUVA therapy represents a sensible alternative for the present.

Back to top
Article Information

Accepted for publication April 14, 1998.

This research was supported in part by General Research Center Grant M01-RR00102 from the National Center for Research Resources at the National Institutes of Health, Bethesda, Md; by NIH grants CA545215, AI39214, and AR07525 from the National Institutes of Health; and by grants or gifts from The Carl J. Herzog Foundation, Greenwich, Conn; the American Skin Association, New York, NY; The Carson Family Charitable Trust, New York, NY; Dr James Murphy, New York, NY; and Jean Stein, New York, NY.

Dr Coven was supported as a Rockefeller University Clinical Scholar from May 1996 through June 1997.

Presented at the 58th meeting of the Society for Investigative Dermatology, Washington, DC, April 26, 1997.

We would like to thank the rotating dermatology residents from The New York Hospital–Cornell Medical Center, New York, NY, for their help with patient care.

Reprints: James G. Krueger, MD, PhD, Laboratory for Investigative Dermatology, The Rockefeller University, Box 178, 1230 York Ave, New York, NY 10021-6399.

Parrish  JAFitzpatrick  TBTannenbaum  LPathak  MA Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med. 1974;2911207- 1211Article
Melski  JWTannenbaum  LParrish  JAFitzpatrick  TBBleich  HL Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol. 1977;68328- 335Article
Greaves  MWWeinstein  GD Treatment of psoriasis. N Engl J Med. 1995;332581- 588Article
Stern  RSNichols  KTVakeva  LH Malignant melanoma in patients treated for psoriasis with methoxysalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med. 1997;3361041- 1045Article
Stern  RSLaird  N The carcinogenic risk of treatments for severe psoriasis. Cancer. 1994;732759- 2764Article
Stern  RSLange  R Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol. 1988;91120- 124Article
Forman  ABRoenigk  HHCaro  WAMagid  ML Long-term follow-up of skin cancer in the PUVA-48 Cooperative Study. Arch Dermatol. 1989;125515- 519Article
Studniberg  HMWeller  P PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol. 1993;291013- 1022Article
Honigsmann  HWolff  KGschnait  FBrenner  WJaschke  E Keratoses and nonmelanoma skin tumors in long-term photochemotherapy. J Am Acad Dermatol. 1980;3406- 414Article
Hannuksela-Svahn  ASigurgeirsson  BPukkala  E  et al. Altmeyer  PedHoffman  KedStucker  Med Trioxsalen bath PUVA does not increase the risk of squamous cell skin carcinoma: a joint analysis of 1124 Swedish and Finnish patients followed up for ten years. Skin Cancer and UV Radiation Berlin, Germany Springer-Verlag Inc1997;434- 439
Hannuksela  APukkala  EHannuksela  MKarvonen  J Cancer incidence among Finnish patients with psoriasis treated with trioxsalen bath PUVA. J Am Acad Dermatol. 1996;35685- 689Article
Lindelof  BSigurgeirsson  BTegner  ELarko  OBerne  B Comparison of the carcinogenic potential of trioxsalen bath PUVA and oral methoxsalen PUVA: a preliminary report. Arch Dermatol. 1992;1281341- 1344Article
Lindelof  BSigurgeirsson  BTegner  E  et al.  PUVA and cancer: a large-scale epidemiological study. Lancet. 1991;33891- 93Article
Berne  BFischer  TMichaelsson  GNoren  P Long-term safety of trioxsalen bath PUVA treatment: an 8-year follow-up of 149 psoriasis patients. Photodermatol. 1984;118- 22
Vallat  VPGilleaudeau  PBattat  L  et al.  PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy. J Exp Med. 1994;180283- 296Article
Gottlieb  SLGilleaudeau  PJohnson  R  et al.  Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med. 1995;1442- 447Article
McKay  IALeigh  IM Altered keratinocyte growth and differentiation in psoriasis. Clin Dermatol. 1995;13105- 114Article
Johnson  RStaiano-Coico  LAustin  LCardinale  LNabeya-Tsukifuji  RKrueger  JG PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in normal and malignant T-lymphocytes. Photochem Photobiol. 1996;63566- 571Article
Yoo  EkRook  AHElenitsas  RGasparro  FPVowels  BR Apoptosis induction of ultraviolet light A and photochemotherapy in cutaneous T-cell lymphoma: relevance to mechanism of therapeutic action. J Invest Dermatol. 1996;107235- 242Article
Koulu  LMJansen  CT Antipsoriatic, erythematogenic, and Langerhans cell marker depleting effect of bath psoralens plus ultraviolet A treatment. J Am Acad Dermatol. 1988;181053- 1059Article
Koulu  LMJansen  CT Effect of oral methoxsalen photochemotherapy on human Langerhans cell number: dose-response and time-sequence studies. Arch Dermatol Res. 1982;27479- 83Article
Friedmann  PSFord  GRoss  JDiffey  BL Reappearance of epidermal Langerhans cells after PUVA therapy. Br J Dermatol. 1983;109301- 307Article
Koulu  LMJansen  CT Skin photosensitizing and Langerhans' cell depleting activity of topical (bath) PUVA therapy: comparison of trimethylpsoralen and 8-methoxypsoralen. Acta Derm Venereol. 1983;63137- 141
Pierard-Franchimont  CNickels-Read  DMosbah  TBEstrada  JAPierard  GE Early dermato-pathological signs during bath-PUVA therapy. J Pathol. 1990;161227- 231Article
Norris  DATravers  JBLeung  DYM Lymphocyte activation in the pathogenesis of psoriasis. J Invest Dermatol. 1997;1091- 4Article
Nestle  FOTurka  LANickoloff  BJ Characterization of dermal dendritic cells in psoriasis: autostimulation of T lymphocytes and induction of Th1 type cytokines. J Clin Invest. 1994;94202- 209Article
Kirkland  DJCreed  KLMannisto  P Comparative bacterial mutagenicity studies with 8-methoxypsoralen and 4,5‘,8-trimethylpsoralen in the presence of near-ultraviolet light and in the dark. Mutat Res. 1983;11673- 82Article
Young  AR Photocarcinogenicity of psoralens used in PUVA treatment: present status in mouse and man. J Photochem Photobiol B. 1990;6237- 247Article
Grossweiner  LI Mechanisms of photosensitization by furocoumarins. Natl Cancer Inst Monogr. 1984;6647- 54
Wolff  KHonigsmann  H Safety and therapeutic effectiveness of selected psoralens in psoriasis. Natl Cancer Inst Monogr. 1984;66159- 164
Cech  TPathak  MABiswas  RK An electron microscopic study of the photochemical cross-linking of DNA in guinea pig epidermis by psoralen derivatives. Biochim Biophys Acta. 1979;562342- 360Article
Pathak  MA Mechanisms of psoralen photosensitization reactions. Natl Cancer Inst Monogr. 1984;6641- 46
Hannuksela  MStenback  FLahti  A The carcinogenic properties of topical PUVA: a lifelong study in mice. Arch Dermatol Res. 1986;278347- 351Article
Krueger  JGWolfe  JTNabeya  RT  et al.  Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med. 1995;1822057- 2068Article
Vaatainen  NTaskinen  J Penetration of trioxsalen into skin from trioxsalen baths. Arch Dermatol Res. 1981;270157- 158Article